The presence of a pituitary tumor on magnetic resonance imaging confirmed the diagnostic hypothesis.
Results show increased hospital charges, costs and length of stay for patients treated by lower-volume surgeons.
Copeptin represents a novel, early marker for postoperative diabetes insipidus after pituitary surgery.
The FDA has approved pasireotide (Signifor long-acting release) for treatment of acromegaly.
Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.
The Endocrine Society has issued a clinical practice guideline for the diagnosis and treatment of acromegaly.
Proton irradiation is an effective treatment for functional pituitary adenomas, and hypopituitarism remains the primary adverse effect.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Gender-Related Association Between Physical Activity, Psychological Status in T2D
- Adverse Neurodevelopmental and Mental Health Outcomes in PCOS
- HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes
- Choroidal Thickness Changes in Patients With Untreated Diabetes
- Pre-Pregnancy Fitness Lowers Gestational Diabetes Risk